-
CorporateEarly diagnosis can make the difference
Early diagnosis can make the difference. That’s the message at the heart of our support for the Irish Pharmaceutical Healthcare Association (IPHA) Innovate For Life 2025 campaign, which this year focuses on early diagnosis and prevention. As part of this advocacy campaign, we’re shining a spotlight on newborn screening – and two family stories in particular – to urge immediate action to implement the Minister of Health’s decision (Nov2023) to include Spinal Muscular Atrophy (SMA) in newborn screening, (ie the heel prick test), by the end of 2025.
Calling for Action. This campaign isn’t just about one or two families – it’s about every family and the 60,000 babies born in Ireland every year. The November 2023 decision to add SMA to the heelprick test needs to be implemented by the end of 2025. #BringSMAtoHeel
Corporate -
CorporateShare your experience of living with Chronic Spontaneous Urticaria (CSU)
Corporate -
CorporateNovartis Ireland launches Patient Choir Contest To Celebrate Eurovision 2025 Sponsorship
Corporate -
Corporate
Celebrating music and patient communities: Novartis Ireland launches the Patient Choir Contest
Corporate -
CorporateCaitriona Walsh: Insights on leadership, innovation, and work-life balance
Corporate -
CorporateNovartis and Deciphex Host Roundtable About Ireland’s AI Sector to Mark Collaboration
Corporate -
CorporateAn Interview with our Novartis Ireland Country President
Corporate -
CorporateMaking Possible: Stepping toward a future with cell and gene therapy
Corporate -
CorporateNovartis utilizing manufacturing capacity to help in the fight against COVID-19
Corporate -
CorporateReimagining Science in #InnovateForLife Campaign
Corporate -
CorporateNovartis Announces Winners of the Innovation Prize for Assistive Tech
Corporate -
CorporateNovartis Ireland is supporting #HoldFirm
Corporate